RCUS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

24.81M

-31.08%

-1.290

+29.03%

30.28M

+8.14%

-1.149

+11.59%

27.44M

-82.85%

-1.070

-6.14%

Estimates Revision

The market is revising Upward the revenue expectations for Arcus Biosciences, Inc. (RCUS) for FY2025, with the revenue forecasts being adjusted by 3.74% over the past three months. During the same period, the stock price has changed by 43.90%.

Revenue Estimates for FY2025

Revise Upward

+3.74%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-5.52%

In Past 3 Month

Stock Price

Go Up

+43.90%

In Past 3 Month

11 Analyst Rating

Wall Street analysts forecast RCUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCUS is 28.38 USD with a low forecast of 14.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

2 Hold

0 Sell

Strong Buy

Current: 0.000

Low

14.00

Averages

28.38

High

56.00

Current: 0.000

Low

14.00

Averages

28.38

High

56.00

Morgan Stanley

Overweight -> Equal Weight

downgrade

$23 -> $20

2026-01-08

New

Reason

Morgan Stanley

Price Target

$23 -> $20

2026-01-08

New

downgrade

Overweight -> Equal Weight

Reason

Morgan Stanley downgraded Arcus Biosciences to Equal Weight from Overweight with a price target of $20, down from $23. The firm sees a more balanced risk/reward at current share levels. Much of the focus for the stock will remain centered on casdatifan, but there are only incremental updates in 2026, the analyst tells investors in a research note.

H.C. Wainwright

Buy

maintain

$28 -> $32

2025-12-12

Reason

H.C. Wainwright

Price Target

$28 -> $32

2025-12-12

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Arcus Biosciences to $32 from $28 and keeps a Buy rating on the shares. The firm updated its model to remove domvanalimab revenues in non-small cell lung cancer and gastrointestinal cancers as it now believes the odds of success for these are 0%, but it simultaneously increased its revenue estimates for casdatifan in second-line clear cell renal cell carcinoma based on highly positive monotherapy data, the analyst tells investors.

Truist

Buy

downgrade

$39 -> $30

2025-12-12

Reason

Truist

Price Target

$39 -> $30

2025-12-12

downgrade

Buy

Reason

Truist lowered the firm's price target on Arcus Biosciences to $30 from $39 and keeps a Buy rating on the shares. Arcus ended the Phase 3 STAR-221 trial after a futile analysis, eliminating domvanalimab+zmberelimab as a near-term catalyst and heightening pessimism around the broader TIGIT program, including Dom in non-small cell lung cancer, the analyst tells investors in a research note. Large R&D cuts are expected as the company pivots toward casdatifan, which remains a potential multi-billion-dollar opportunity backed by about $1B in cash and multiple 2026 catalysts.

Citi

Yigal Nochomovitz

Buy

downgrade

$56 -> $44

2025-12-12

Reason

Citi

Yigal Nochomovitz

Price Target

$56 -> $44

2025-12-12

downgrade

Buy

Reason

Citi analyst Yigal Nochomovitz lowered the firm's price target on Arcus Biosciences to $44 from $56 and keeps a Buy rating on the shares after the company announced that the Phase 3 STAR-221 trial has been discontinued due to futility observed at a pre-specified interim analysis. Following the news, the firm has removed domvanalimab plus zimberelimab in gastric-related indications from its valuation, but remains positive on casdatifan ahead of readouts in 2026, the analyst tells investors.

BofA

Neutral

maintain

$17 -> $26

2025-11-28

Reason

BofA

Price Target

$17 -> $26

2025-11-28

maintain

Neutral

Reason

BofA raised the firm's price target on Arcus Biosciences to $26 from $17 and keeps a Neutral rating on the shares after incorporating Taiho's option of RCC candidate casdatifan in its Arcus model while making "limited adjustments" to its forecasts following the company's Q3 earnings update.

Goldman Sachs

Salveen Richter

Neutral

maintain

$14 -> $16

2025-10-30

Reason

Goldman Sachs

Salveen Richter

Price Target

$14 -> $16

2025-10-30

maintain

Neutral

Reason

Goldman Sachs analyst Salveen Richter raised the firm's price target on Arcus Biosciences (RCUS) to $16 from $14 and keeps a Neutral rating on the shares. Arcus reported Q3 EPS and provided updates and timelines for its programs, including casdatifan in clear-cell renal cell carcinoma, where the Phase 3 study in the post-IO setting continues to enroll, but enrollment has been paused for the Phase 1b/3 1L trial to assess the combination regimen's safety profile, the analyst tells investors in a research note. Goldman continues to view cas's profile as differentiated vs. Merck's (MRK) competitor drug Welireg.

Valuation Metrics

The current forward P/E ratio for Arcus Biosciences Inc (RCUS.N) is -5.73, compared to its 5-year average forward P/E of -6.27. For a more detailed relative valuation and DCF analysis to assess Arcus Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.27

Current PE

-5.73

Overvalued PE

-2.27

Undervalued PE

-10.26

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.81

Current EV/EBITDA

-5.19

Overvalued EV/EBITDA

0.88

Undervalued EV/EBITDA

-8.50

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

14.00

Current PS

26.43

Overvalued PS

20.46

Undervalued PS

7.53

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 186.42% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

RCUS News & Events

Events Timeline

No data

News

9.0

01-07Newsfilter

PinnedArcus Advances Casdatifan Phase 3 Trials, Plans Three Data Presentations in 2026

5.0

01-06Fool

Arcus Biosciences President Sells 82,997 Shares for Over $2.05 Million

5.0

01-06NASDAQ.COM

Arcus Biosciences Insider Sells 82,997 Shares for $2.1 Million Amid Market Highs

People Also Watch

Frequently Asked Questions

What is Arcus Biosciences Inc (RCUS) stock price today?

The current price of RCUS is 21.01 USD — it has decreased -1.59 % in the last trading day.

What is Arcus Biosciences Inc (RCUS)'s business?

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

What is the price predicton of RCUS Stock?

What is Arcus Biosciences Inc (RCUS)'s revenue for the last quarter?

Arcus Biosciences Inc revenue for the last quarter amounts to 26.00M USD, decreased -45.83 % YoY.

What is Arcus Biosciences Inc (RCUS)'s earnings per share (EPS) for the last quarter?

Arcus Biosciences Inc. EPS for the last quarter amounts to -1.27 USD, increased 25.74 % YoY.

What changes have occurred in the market's expectations for Arcus Biosciences Inc (RCUS)'s fundamentals?

How many employees does Arcus Biosciences Inc (RCUS). have?

Arcus Biosciences Inc (RCUS) has 627 emplpoyees as of January 10 2026.

What is Arcus Biosciences Inc (RCUS) market cap?

Today RCUS has the market capitalization of 2.56B USD.